Yes, bisoprolol is cardioselective (beta-1 selective)
Bisoprolol is a beta-1 selective (cardioselective) adrenoceptor blocking agent that preferentially blocks beta-1 receptors in the heart while having minimal effect on beta-2 receptors in the bronchial and vascular smooth muscle at therapeutic doses 1.
Key Pharmacologic Properties
According to FDA labeling, bisoprolol is classified as a beta-1 selective agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range 1. This cardioselectivity is explicitly recognized in major clinical guidelines, which consistently categorize bisoprolol under "Beta blockers—cardioselective" 2, 3, 4.
Important Clinical Caveat About Selectivity
Cardioselectivity is not absolute and is dose-dependent. At higher doses (≥20 mg), bisoprolol also inhibits beta-2 adrenoceptors located in bronchial and vascular musculature 1. To maintain selectivity, it is essential to use the lowest effective dose.
Similarly, both metoprolol tartrate and bisoprolol may lose their beta-1 selectivity when prescribed in the higher doses that have been associated with improved survival in heart failure patients 5.
Clinical Implications of Cardioselectivity
In Patients with Respiratory Disease
- Bisoprolol is preferred in patients with bronchospastic airway disease requiring a beta-blocker 2, 3, 4
- If concomitant reactive airways disease is present, consider using more selective beta-1 blockade such as bisoprolol 6
- Beta-blockers are only relatively contraindicated in asthma, but not in COPD, though a more selective beta-1 blocker (bisoprolol, metoprolol succinate, or nebivolol) is preferred 7
- Most patients with chronic obstructive pulmonary disease do not have a bronchospastic component and remain reasonable candidates for beta-blockade 5
Comparison with Other Beta-Blockers
The major guidelines distinguish bisoprolol from:
- Noncardioselective beta-blockers (nadolol, propranolol) which should be avoided in patients with reactive airways disease 2, 3, 4
- Combined alpha- and beta-receptor blockers (carvedilol, labetalol) which are nonselective 2, 3, 4
Evidence in Heart Failure
Bisoprolol, along with metoprolol succinate, is preferred in patients with heart failure with reduced ejection fraction (HFrEF) 2, 3. The CIBIS-II trial demonstrated that bisoprolol significantly reduced all-cause mortality by 34% (RR 0.66,95% CI 0.54-0.81) in patients with moderate to severe heart failure 8, 9.
The cardioselectivity of bisoprolol makes it a particularly valuable option when beta-blockade is needed in patients with both cardiovascular disease and respiratory comorbidities, though careful dose titration and monitoring remain essential.